Microbot Medical Inc. announced on October 15, 2024, the successful completion of enrollment and follow-up for all patients in its ACCESS-PVI human clinical trial. This pivotal trial evaluated the performance and safety of the LIBERTY Endovascular Robotic Surgical System in human subjects undergoing Peripheral Vascular Interventions.
The company remains on track to file its 510(k) submission with the U.S. Food and Drug Administration (FDA) by the end of 2024. This achievement is a monumental moment for Microbot Medical, as stated by CEO Harel Gadot.
In conjunction with the trial completion, Microbot Medical is accelerating its go-to-market strategy, with plans to build out its commercial infrastructure and hire a seasoned healthcare executive to lead sales efforts. The company anticipates the FDA clearance and subsequent commercial launch of LIBERTY during the second quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.